Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM) Share Price

Price 194.00p on 16-09-2026 at 16:15:00
Change -7.00p -3.48%
Buy 205.00p
Sell 194.50p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 12.00 at 194.00p
Day's Volume: 3,697
Last Close: 194.00p
Open: 204.00p
ISIN: KYG4672N1198
Day's Range 194.00p - 205.00p
52wk Range: 153.00p - 264.00p
Market Capitalisation: £1.69b
VWAP: 201.9342p
Shares in Issue: 869.07m

Sector: Medicine and Biotech

Listed In: FTSE AIM 100, FTSE AIM All-Share,

Hutchmed (HCM) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 12 194.00p Uncrossing Trade
 16:40:43 - 16-Sep-26
Buy* 1 203.30p Ordinary
 15:55:20 - 16-Sep-26
Buy* 9 205.00p Automatic Execution
 15:25:44 - 16-Sep-26
Buy* 10 204.00p Automatic Execution
 15:25:44 - 16-Sep-26
Sell* 16 198.137p Negotiated Trade
 15:16:05 - 16-Sep-26
Sell* 11 195.00p SI Trade
 14:30:02 - 16-Sep-26
Sell* 2 195.00p SI Trade
 14:30:02 - 16-Sep-26
Buy* 2,200 203.425p Ordinary
 11:09:05 - 16-Sep-26
Sell* 510 197.126p Negotiated Trade
 09:14:17 - 16-Sep-26
Sell* 848 201.00p Automatic Execution
 08:15:21 - 16-Sep-26
See more Hutchmed trades

Hutchmed (HCM) Share Price History

Time period:
to
Date Open High Low Close Volume
15th Sep 2026 (Tue) 204.00 204.00 201.00 201.00 27,765
14th Sep 2026 (Mon) 197.00 205.00 197.00 199.00 500,612
11th Sep 2026 (Fri) 195.00 196.50 192.00 192.00 7,070
10th Sep 2026 (Thu) 201.00 201.00 197.00 200.00 21,068
9th Sep 2026 (Wed) 212.00 212.00 202.00 202.00 4,100
8th Sep 2026 (Tue) 205.00 206.00 204.00 204.00 5,825
7th Sep 2026 (Mon) 212.00 212.00 207.00 207.00 22,300
4th Sep 2026 (Fri) 212.00 217.00 210.00 212.00 121,292
3rd Sep 2026 (Thu) 202.00 210.00 201.00 209.00 497,827
2nd Sep 2026 (Wed) 178.50 179.50 178.00 179.50 3,307
1st Sep 2026 (Tue) 182.00 182.00 177.00 177.00 16,639
31st Aug 2026 (Mon) 181.00 181.00 181.00 181.00 0
28th Aug 2026 (Fri) 181.00 181.00 181.00 181.00 275
27th Aug 2026 (Thu) 187.00 190.50 182.50 182.50 18,088
26th Aug 2026 (Wed) 179.00 187.00 179.00 183.00 16,057
25th Aug 2026 (Tue) 180.00 182.50 179.00 179.00 2,025
24th Aug 2026 (Mon) 181.50 182.00 178.00 178.00 10,391
21st Aug 2026 (Fri) 182.00 190.50 182.00 184.00 844
20th Aug 2026 (Thu) 189.00 189.00 182.00 182.00 35,869
19th Aug 2026 (Wed) 185.00 185.50 183.00 183.00 40,836
18th Aug 2026 (Tue) 192.50 195.00 187.50 189.00 65,668
17th Aug 2026 (Mon) 190.50 191.00 189.50 190.00 43,964
See more Hutchmed price history

Hutchmed (HCM) Regulatory News

Date Source Headline
3rd Sep 2026 7:00 am RNS HUTCHMED Licenses KRAS-EGFR-Antibody to GSK
1st Sep 2026 7:00 am RNS SANOVO trial demonstrated significant PFS benefit
28th Aug 2026 7:00 am RNS NMPA Approval for ATLED® (Fanregratinib) for ICC
18th Aug 2026 10:00 am RNS Announcement pursuant to AIM Rule 17 Schedule 2(g)
17th Aug 2026 7:00 am RNS Orpathys+Tagrisso improved PFS & OS in EGFRm lung
30th Jul 2026 12:00 pm RNS HUTCHMED Reports 2026 Interim Results
2nd Jul 2026 9:30 am RNS HUTCHMED Announces NMPA Approval for ORPATHYS
30th Jun 2026 9:30 am RNS HUTCHMED to Announce 2026 Half-Year Results
29th Jun 2026 9:30 am RNS Announcement on blocklisting six monthly return
25th Jun 2026 7:00 am RNS-R HUTCHMED Highlights Phase II Data at ESMO
See more Hutchmed regulatory news

Hutchmed (HCM) Share News

LONDON MARKET MIDDAY: FTSE 100 edges higher; oil rises above USD97

3rd Sep 2026 12:10

(Alliance News) - Stock prices in London were higher at midday on Thursday, as gains for telecom stocks helped the FTSE 100 edge into positive territory, while investors digested stronger UK services activity and rising inflationary pressures in Europe. Read More

WINNERS & LOSERS: Hutchmed pens GSK deal; Gem Diamonds back in profit

3rd Sep 2026 11:20

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday. Read More

Hutchmed China inks USD1.30 billion GSK deal for cancer drug HMPL-A830

3rd Sep 2026 10:22

(Alliance News) - Hutchmed China PLC on Thursday announced that its subsidiary, Hutchmed Ltd, has entered into an exclusive development licence agreement with a subsidiary of GSK PLC. Read More

LONDON BRIEFING: LondonMetric investments; Jet2 eyes Main Market move

3rd Sep 2026 07:56

(Alliance News) - M&G swings to a first-half pretax loss attributable to equity holders as short-term investment fluctuations weigh on statutory results, while LondonMetric Property announces GBP105 million of investment activity. Elsewhere, Jet2 says trading remains strong and announces plans to move from AIM to London's Main Market. Read More

IN BRIEF: Hutchmed "thrilled" by positive phase 3 trial results

1st Sep 2026 13:37

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Announces "positive high-level results" from the Sanovo China phase 3 trial of Orpathys plus Tagrisso in treatment-naive patients with locally advanced or metastatic non-small cell lung cancer, whose tumours harbour epidermal growth factor receptor mutation and MET overexpression. Orpathys, or savolitinib, combined with Tagrisso or osimertinib, showed "a statistically significant and highly clinically meaningful improvement in progression-free survival" in the high MET and intention-to-treat patient populations, compared with Tagrisso alone. Hutchmed adds that "the combination also demonstrated a very encouraging clinical benefit in [the secondary endpoint of] overall survival" in both populations. Hutchmed is jointly developing Orpathys with AstraZeneca, which is also commercialising the treatment. Read More

See more Hutchmed news
FTSE 100 Latest
Value10,688.47
Change30.34

Login to your account

Forgot Password?

Not Registered